6.54

3.81% +0.24

Pre-market: 6.73 0.19 +2.91%

C4 Therapeutics Inc (CCCC)

Overview News Price History Option Chain Financials Discussions Forecast

C4 Therapeutics Inc stock is currently priced at $6.54, with a 24-hour trading volume of 1.81M. It has seen a +3.81% increased in the last 24 hours and a -19.26% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $6.28 pivot point. If it approaches the $6.61 resistance level, significant changes may occur.

Previous Close:

$6.30

Open:

$6.34

24h Volume:

1.81M

Market Cap:

$448.65M

Revenue:

$20.76M

Net Income/Loss:

$-132.49M

P/E Ratio:

-2.2947

EPS:

-2.85

Net Cash Flow:

$-108.55M

1W Performance:

+1.08%

1M Performance:

-19.26%

6M Performance:

+395.45%

1Y Performance:

+101.85%

1D Range:

$6.22

$6.61

52W Range:

$1.06

$11.88

C4 Therapeutics Inc Stock (CCCC) Company Profile

Name

C4 Therapeutics Inc

Sector

Healthcare (1189)

Industry

Biotechnology (685)

Phone

617 231 0700

Address

490 Arsenal Way, Suite 200, Watertown

Employee

Twitter

Next Earnings Date

2024-05-02

Latest SEC Filings

CCCC's Discussions on Twitter

C4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-24-23	Upgrade	Credit Suisse	Underperform → Neutral
Feb-24-23	Downgrade	JP Morgan	Neutral → Underweight
Nov-04-22	Downgrade	JP Morgan	Overweight → Neutral
Oct-11-22	Initiated	Morgan Stanley	Underweight
Apr-28-22	Initiated	Credit Suisse	Underperform
Apr-11-22	Downgrade	BofA Securities	Buy → Neutral
Mar-10-22	Initiated	JP Morgan	Overweight
Feb-11-22	Resumed	BMO Capital Markets	Outperform
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Nov-23-21	Initiated	BofA Securities	Buy
Oct-14-21	Initiated	SVB Leerink	Mkt Perform
Sep-30-21	Initiated	Stifel	Hold
Jun-04-21	Initiated	H.C. Wainwright	Buy
Mar-31-21	Initiated	BMO Capital Markets	Outperform
Oct-28-20	Initiated	UBS	Buy
Oct-27-20	Initiated	BMO Capital Markets	Outperform
Oct-27-20	Initiated	Jefferies	Buy

View All

C4 Therapeutics Inc Stock (CCCC) Latest News

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

GlobeNewswire Inc.

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

GlobeNewswire Inc.

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

GlobeNewswire Inc.

Breaking Down C4 Therapeutics: 4 Analysts Share Their Views

Benzinga

C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Misses Revenue Estimates

Zacks Investment Research

C4 Therapeutics Inc Stock (CCCC) Financials Data

C4 Therapeutics Inc (CCCC) Revenue 2024

CCCC reported a revenue (TTM) of $20.76 million for the quarter ending December 31, 2023, a -33.25% decline year-over-year.

C4 Therapeutics Inc (CCCC) Net Income 2024

CCCC net income (TTM) was -$132.49 million for the quarter ending December 31, 2023, a -3.37% decrease year-over-year.

C4 Therapeutics Inc (CCCC) Cash Flow 2024

CCCC recorded a free cash flow (TTM) of -$108.55 million for the quarter ending December 31, 2023, a +2.59% increase year-over-year.

C4 Therapeutics Inc (CCCC) Earnings per Share 2024

CCCC earnings per share (TTM) was -$2.67 for the quarter ending December 31, 2023, a -1.91% decline year-over-year.

C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma, peripheral T-cell lymphoma, and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid malignancies; and BRAF V600E and RET programs for genetically defined resistant solid tumors. It has strategic collaborations with F. Hoffman-La Roche Ltd.; Biogen, Inc.; and Calico Life Sciences LLC. C4 Therapeutics, Inc. was founded in 2015 and is headquartered in Watertown, Massachusetts.